IP Library › Granted Patent US 11,180,574
Granted Patent B2
US 11,180,574 · App. 16/796,063 · Granted Nov 23, 2021

Method and carrier complexes for delivering molecules to cells

Inventors: Hazel H. Szeto (New York, NY); Kesheng Zhao (Jackson Heights, NY); Hugh Robertson (New York, NY); Alex V. Birk (Woodhaven, NY)
Assignee: CORNELL RESEARCH FOUNDATION INC.
C07K17/00A61K31/713A61K38/47A61K47/64A61K47/645C07K5/08C07K5/1016C07K5/1019C12N9/2471C12N9/96C12N15/113C12N15/87C12Y302/01023C12N2310/3513C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,180,574
App. No.
16/796,063
Granted
Nov 23, 2021
Kind
B2
Abstract

The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.

Claims (30)

1. A carrier complex comprising a molecule conjugated to an aromatic cationic peptide, wherein the aromatic cationic peptide is selected from the group consisting of Tyr-D-Arg-Phe-Lys-NH 2 (DALDA), 2′,6′-Dmt-D-Arg-Phe-Lys-NH 2 (Dmt 1 -DALDA), Phe-D-Arg-Phe-Lys-NH 2 (Phe 1 -DALDA), D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 and 2′,6′-Dmp-D-Arg-Phe-Lys-NH 2 (Dmp 1 -DALDA); and wherein the molecule is a peptide nucleic acid.

2. The carrier complex according to claim 1 , wherein the peptide has the formula Tyr-D-Arg-Phe-Lys-NH 2 (DALDA).

3. The carrier complex according to claim 1 , wherein the peptide has the formula 2′,6′-Dmt-D-Arg-Phe-Lys-NH 2 (Dmt 1 -DALDA).

4. The carrier complex according to claim 1 , wherein the peptide has the formula Phe-D-Arg-Phe-Lys-NH 2 (Phe 1 -DALDA).

5. The carrier complex according to claim 1 , wherein the peptide has the formula D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 .

6. The carrier complex according to claim 1 , wherein the peptide has the formula 2′,6′-Dmp-D-Arg-Phe-Lys-NH 2 (Dmp 1 -DALDA).

7. The carrier complex according to claim 1 , wherein the aromatic cationic peptide comprises a linker.

8. The carrier complex according to claim 1 , wherein the molecule comprises a linker.

9. The carrier complex according to claim 1 , wherein the molecule and aromatic cationic peptide are chemically bonded.

10. The carrier complex according to claim 1 , wherein the molecule and aromatic cationic peptide are physically bonded.

11. A method for delivering a molecule to a cell, the method comprising contacting the cell with a carrier complex, wherein the carrier complex comprises the molecule conjugated to an aromatic cationic peptide, wherein the aromatic cationic peptide is selected from the group consisting of Tyr-D-Arg-Phe-Lys-NH 2 (DALDA), 2′,6′-Dmt-D-Arg-Phe Lys-NH 2 (Dmt 1 -DALDA), Phe-D-Arg-Phe-Lys-NH 2 (Phe 1 -DALDA), D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 , and 2′,6′-Dmp-D-Arg-Phe-Lys-NH 2 (Dmp 1 -DALDA); and wherein the molecule is a peptide nucleic acid.

12. The method according to claim 11 , wherein the peptide has the formula Tyr-D-Arg-Phe-Lys-NH 2 (DALDA).

13. The method according to claim 11 , wherein the peptide has the formula 2′,6′-Dmt-D-Arg-Phe-Lys-NH 2 (Dmt 1 -DALDA).

14. The method according to claim 11 , wherein the peptide has the formula Phe-D-Arg-Phe-Lys-NH 2 (Phe 1 -DALDA).

15. The method according to claim 11 , wherein the peptide has the formula D-Arg-2′6′-Dmt-Lys-Phe-NH 2 .

16. The method according to claim 11 , wherein the peptide has the formula 2,6′-Dmp-D-Arg-Phe-Lys-NH 2 (Dmp 1 -DALDA).

17. The method according to claim 11 , wherein the cell is a bacterial cell.

18. The method according to claim 11 , wherein the cell is an animal cell.

19. The method according to claim 18 , wherein the animal cell is a mammalian cell.

20. The method according to claim 18 , wherein the cell is a neuronal cell.

21. The method according to claim 18 , wherein the cell is a renal epithelial cell.

22. The method according to claim 18 , wherein the cell is an intestinal epithelial cell.

23. The method according to claim 18 , wherein the cell is a vascular endothelial cell.

24. The method according to claim 18 , wherein the endothelial cell is a blood-brain barrier endothelial cell.

25. The method according to claim 18 , wherein the cell is a glial cell.

26. The method according to claim 18 , wherein the cell is a hepatocyte.

27. The method according to claim 11 , wherein the aromatic cationic peptide comprises a linker.

28. The method according to claim 11 , wherein the molecule comprises a linker.

29. The method according to claim 11 , wherein the molecule and aromatic cationic peptide are chemically bonded.

30. The method according to claim 11 , wherein the molecule and aromatic cationic peptide are chemically bonded.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2021
From: SZETO, HAZEL H.; ZHAO, KESHENG; ROBERTSON, HUGH D.; BIRK, ALEX V.
To: CORNELL RESEARCH FOUNDATION, INC.
Reel/Frame 057848/0963 →
Continuity (6)
Continuation 15067726 · Mar 11, 2016
Continuation 13422722 · Mar 16, 2012
Continuation 12631048 · Dec 4, 2009
Continuation 10838135 · May 3, 2004
Provisional Application 60467516 · May 1, 2003
Related Publication 20200299415A1 · Sep 24, 2020